BridgeMD
New treatment option for Cancer Of Prostate
Official title A Phase I/II Study of PDS01ADC With Docetaxel and Abiraterone in Adults With Metastatic Castration Sensitive and PDS01ADC With Docetaxel in Castration Resistant Prostate Cancer
ClinicalTrials.gov ID: NCT04633252
What this study is testing
What is PDS01ADC?
PDS01ADC is an investigational medicine, given as an once-daily injection under the skin, being studied as a potential treatment for cancer of prostate.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- Background: Metastatic castration sensitive and castration resistant prostate cancer (mCSPC and mCRPC) are prostate cancers that have spread to other parts of the body. Use of the drug docetaxel with androgen deprivation therapy can improve survival for men with mCSPC.
- Phase 2: a mid-size study of how well it works
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 110, men only
You may be able to join if
- Participants must have documented histopathological confirmation of prostate cancer. If no pathologic specimen is available, participants may enroll...
- Participants must have metastatic disease, defined as at least one lesion on TC99 bone scan or at least one lesion that is measurable per, per RECIST...
- mCSPC participants:
- Participants must be within 134 days of starting ADT.
- If participants are on ADT and responding, this may impact the findings on scans. Pre- treatment scans could be used to confirm that participants...
You likely can't join if
- Immunocompromised status due to:
- Human immunodeficiency virus (HIV) positivity
- Active autoimmune diseases such as Addison's disease, Hashimoto's thyroiditis, systemic lupus erythematosus, Sjogren syndrome, scleroderma...
- Other immunodeficiency diseases that in the opinion of the investigator could compromise the participant or limit treatment how well it works
- Serious intercurrent medical illness that, in the judgment of the investigator, would interfere with participant s ability to carry out the treatment...
- Current use of other medications for urinary symptoms including 5-alpha reductase inhibitors (finasteride and dutasteride) and alternative...
See the full eligibility criteria
Who can join
- Participants must have documented histopathological confirmation of prostate cancer. If no pathologic specimen is available, participants may enroll with a pathologist's report showing a histologic diagnosis of prostate...
- Participants must have metastatic disease, defined as at least one lesion on TC99 bone scan or at least one lesion that is measurable per, per RECIST 1.1.
- mCSPC participants:
- Participants must be within 134 days of starting ADT.
- If participants are on ADT and responding, this may impact the findings on scans. Pre- treatment scans could be used to confirm that participants have metastatic high-volume disease in such cases.
- For Cohorts 1 and 2, Dose escalation and Safety Run-in, only: mCSPC may have high or low volume disease.
- For Cohort 3, Dose Expansion: mCSPC participants must have high volume disease (as defined by visceral lesion or 4 or greater bone lesions, at least one of which is beyond the spine and pelvis).
- mCRPC participants:
- Must need ADT as part of their cancer therapy (unless previous orchiectomy)
- Must have been previously treated with modern anti-androgens such as abiraterone, enzalutamide, apalutamide, or darolutamide.
- Must have not had progression while on docetaxel if given for mCSPC or within 3 months of completing docetaxel for mCSPC.
- Progression defined as either rising PSA greater than 2.0 ng/ml or radiographic evidence of progression seen on CT scan or TC-99 bone scan.
- Toxicities related to prior therapy, including surgery and/ or radiation, must have resolved to \<= grade 1.
- Men age \>=18 years. Because no dosing or adverse event data are currently available on the use of
- Participants must have documented histopathological confirmation of prostate cancer. If no pathologic specimen is available, participants may enroll with a pathologist's report showing a histologic diagnosis of prostate...
- Participants must have metastatic disease, defined as at least one lesion on TC99 bone scan or at least one lesion that is measurable per, per RECIST 1.1.
- mCSPC participants:
- Participants must be within 134 days of starting ADT.
- If participants are on ADT and responding, this may impact the findings on scans. Pre- treatment scans could be used to confirm that participants have metastatic high-volume disease in such cases.
- For Cohorts 1 and 2, Dose escalation and Safety Run-in, only: mCSPC may have high or low volume disease.
- For Cohort 3, Dose Expansion: mCSPC participants must have high volume disease (as defined by visceral lesion or 4 or greater bone lesions, at least one of which is beyond the spine and pelvis).
- mCRPC participants:
- Must need ADT as part of their cancer therapy (unless previous orchiectomy)
- Must have been previously treated with modern anti-androgens such as abiraterone, enzalutamide, apalutamide, or darolutamide.
- Must have not had progression while on docetaxel if given for mCSPC or within 3 months of completing docetaxel for mCSPC.
- Progression defined as either rising PSA greater than 2.0 ng/ml or radiographic evidence of progression seen on CT scan or TC-99 bone scan.
- Toxicities related to prior therapy, including surgery and/ or radiation, must have resolved to \<= grade 1.
- Men age \>=18 years. Because no dosing or adverse event data are currently available on the use of PDS01ADC in combination with docetaxel in participants \<18 years of age, children are excluded from this study.
- ECOG performance status 0-2.
- Participants must have adequate organ and marrow function as defined below:
- Absolute neutrophil count \>=1,500/mcL, without CSF support
- Platelets \>=100,000/mcL
- Hemoglobin \>9 g/dL
- PT \<= 1.5 x ULN
- aPTT \<= 1.5 x ULN
- Total bilirubin \<= upper limit of normal (ULN), OR in participants with Gilbert's syndrome, a total bilirubin \<= 3.0
- Serum albumin \>=2.8 g/dL
- AST(SGOT)/ALT(SGPT) \<=1.5 X institutional upper limit of normal \-- Hepatic function based on Child-Pugh Class: Participants with hepatic impairment must have Child-Pugh Class A or better
- Serum Creatinine OR Creatinine Clearance \ =50 mL/min/1.73 m\^2 calculated by eGFR in the clinical lab for participants with serum creatinine levels \> 1.5 ULN
- The effects of PDS01ADC in combination with docetaxel and abiraterone on the developing human fetus are unknown. For this reason and because docetaxel agents as well as other immuno-therapeutic agents used in this trial...
- Ability of subject to understand and the willingness to sign a written informed consent document. Subject should be willing to travel to the NIH for follow-up visits.
- Participants with prior immune checkpoint therapy are eligible to enroll upon PI discretion.
What rules you out
- Immunocompromised status due to:
- Human immunodeficiency virus (HIV) positivity
- Active autoimmune diseases such as Addison's disease, Hashimoto's thyroiditis, systemic lupus erythematosus, Sjogren syndrome, scleroderma, myasthenia gravis, Goodpasture syndrome or active Grave's disease. Participants...
- Other immunodeficiency diseases that in the opinion of the investigator could compromise the participant or limit treatment how well it works
- Serious intercurrent medical illness that, in the judgment of the investigator, would interfere with participant s ability to carry out the treatment program.
- Current use of other medications for urinary symptoms including 5-alpha reductase inhibitors (finasteride and dutasteride) and alternative medications known to alter PSA (e.g. phytoestrogens and saw palmetto).
- Concurrent use of CYP3A4 inducers or sensitive CYP2D6 substrates within 14 days or 5 half-lives, whichever is shorter.
- Receipt of any investigational agent within 28 days (or 60 days for an antibody drug conjugates) before the first planned dose of study drugs.
- Participants who are positive for Hepatitis B surface antigen and/or Anti-Hepatitis C antibody
- Uncontrolled hypertension (SBP\>170/ DBP\>105)
- Has received or will receive a live vaccine within 30 days prior to the first administration of study intervention. Seasonal flu vaccines that do not contain a live virus are permitted. Locally approved COVID vaccines...
- Participants who have had prior docetaxel for mCRPC
- mCSPC participants will be excluded if they did not start abiraterone within 6 weeks of ADT and/or had any docetaxel
- Participants who have had progression within 3 months of completing docetaxel for mCSPC
- History of allergic reactions attributed to compounds of similar chemical or biologic composition to PDS01ADC investigational agents used in the study
- The subject has had evidence within 3 years of the start of study treatment of another active malignancy which required systemic treatment (except for nonmelanoma skin cancers or carcinoma in situ of the bladder).
- The subject has active brain metastases or epidural disease.
- Participants with greater than or equal to grade 2 peripheral neuropathy (defined by CTCAE 5.0) at baseline.
The study team makes the final eligibility decision.
Where it's taking place
- Bethesda, Maryland, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling male, 18 years to 110 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Bethesda, Maryland, United States. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.